Year All2024202320222021202020192018201720162014201320112010 June 25, 2018 Rhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares June 20, 2018 Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering June 18, 2018 Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering June 18, 2018 Rhythm Pharmaceuticals Announces New Topline Clinical Data from Ongoing Phase 2 Basket Studies Evaluating Setmelanotide in Rare Genetic Disorders of Obesity June 14, 2018 Rhythm Pharmaceuticals Completes Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating Setmelanotide in Rare Genetic Disorders of Obesity June 1, 2018 Rhythm Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference May 14, 2018 Rhythm Pharmaceuticals Reports First Quarter 2018 Financial Results May 9, 2018 Rhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 Study of Setmelanotide for Treatment of LEPR Deficiency Obesity May 9, 2018 Rhythm Pharmaceuticals to Present at the Bank of America Merrill Lynch 2018 Health Care Conference April 2, 2018 Rhythm Pharmaceuticals Announces Licensing Agreement with Takeda for the Development and Commercialization of Preclinical Treatment for Prader-Willi Syndrome
June 25, 2018 Rhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
June 18, 2018 Rhythm Pharmaceuticals Announces New Topline Clinical Data from Ongoing Phase 2 Basket Studies Evaluating Setmelanotide in Rare Genetic Disorders of Obesity
June 14, 2018 Rhythm Pharmaceuticals Completes Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating Setmelanotide in Rare Genetic Disorders of Obesity
May 9, 2018 Rhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 Study of Setmelanotide for Treatment of LEPR Deficiency Obesity
May 9, 2018 Rhythm Pharmaceuticals to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
April 2, 2018 Rhythm Pharmaceuticals Announces Licensing Agreement with Takeda for the Development and Commercialization of Preclinical Treatment for Prader-Willi Syndrome
